Latest filings (excl ownership)
15-12B
Securities registration termination
21 May 20
EFFECT
Notice of effectiveness
19 May 20
EFFECT
Notice of effectiveness
19 May 20
EFFECT
Notice of effectiveness
19 May 20
EFFECT
Notice of effectiveness
19 May 20
POS AM
Prospectus update (post-effective amendment)
14 May 20
POS AM
Prospectus update (post-effective amendment)
14 May 20
POS AM
Prospectus update (post-effective amendment)
14 May 20
POSASR
Automatic shelf registration (post-effective amendment)
14 May 20
POS AM
Prospectus update (post-effective amendment)
14 May 20
S-8 POS
Registration of securities for employees (post-effective amendment)
14 May 20
S-8 POS
Registration of securities for employees (post-effective amendment)
14 May 20
S-8 POS
Registration of securities for employees (post-effective amendment)
14 May 20
S-8 POS
Registration of securities for employees (post-effective amendment)
14 May 20
S-8 POS
Registration of securities for employees (post-effective amendment)
14 May 20
S-8 POS
Registration of securities for employees (post-effective amendment)
14 May 20
S-8 POS
Registration of securities for employees (post-effective amendment)
14 May 20
8-K
Material Modifications to Rights of Security Holders
14 May 20
25-NSE
Exchange delisting
11 May 20
8-K
AbbVie Inc. Completes Acquisition of Allergan plc
8 May 20
10-Q
2020 Q1
Quarterly report
7 May 20
8-K
Announcement relating to the outcome of the Court Sanction Hearing
6 May 20
10-K/A
2019 FY
Annual report (amended)
29 Apr 20
8-K
Temporary Suspension of Trading Under Registrant's Employee Benefit Plans
21 Apr 20
8-K
AbbVie and Allergan Sign Consent Decree Agreement with Federal Trade Commission Staff on Pending Transaction
18 Mar 20
8-K
AbbVie and Allergan Receive Final European Approval to Close Pending Transaction
3 Mar 20
10-K
2019 FY
Annual report
18 Feb 20
8-K
Allergan Reports Fourth Quarter and Full-Year 2019 Financial Results
10 Feb 20
8-K
AbbVie and Allergan Announce Agreements to Divest Brazikumab and Zenpep
27 Jan 20
10-Q
2019 Q3
Quarterly report
5 Nov 19
8-K
Third Quarter 2019 Financial Results—Frequently Asked Questions
5 Nov 19
8-K
Allergan Reports Third Quarter 2019 Financial Results
5 Nov 19
8-K
Allergan Shareholders Approve Proposed Acquisition by AbbVie
15 Oct 19
DEFA14A
Additional proxy soliciting materials
3 Oct 19
DEFA14A
Additional proxy soliciting materials
27 Sep 19
8-K
Other Events
27 Sep 19
8-K
Report of Pricewaterhousecoopers Ireland on Allergan Profit
16 Sep 19
DEFM14A
Proxy related to merger
16 Sep 19
8-K
Other Events
11 Sep 19
DEFA14A
Additional proxy soliciting materials
11 Sep 19
Latest ownership filings
4
Nesli Basgoz
12 May 20
4
Joseph H Boccuzi
12 May 20
4
ROBERT J HUGIN
11 May 20
4
CHRIS W BODINE
11 May 20
4
James DArecca
11 May 20
4
Adriane M Brown
11 May 20
4
A Robert D Bailey
11 May 20
4
THOMAS C FREYMAN
11 May 20
4
MATTHEW M WALSH
11 May 20
4
CAROL ANTHONY DAVIDSON
11 May 20
4
Wayne R Swanton
11 May 20
4
C. David Nicholson
11 May 20
4
Michael Eldon Greenberg
11 May 20
4
William Meury
11 May 20
4
Peter J McDonnell
11 May 20
4
BRENT L SAUNDERS
11 May 20
4
CHRISTOPHER J COUGHLIN
11 May 20
4
Nesli Basgoz
4 May 20
4
CHRISTOPHER J COUGHLIN
4 May 20
4
CAROL ANTHONY DAVIDSON
4 May 20
4
Adriane M Brown
4 May 20
4
Michael Eldon Greenberg
4 May 20
4
THOMAS C FREYMAN
4 May 20
4
Joseph H Boccuzi
4 May 20
4
CHRIS W BODINE
4 May 20
4
ROBERT J HUGIN
4 May 20
4
Peter J McDonnell
4 May 20
4
C. David Nicholson
7 Apr 20
4
William Meury
7 Apr 20
4
A Robert D Bailey
7 Apr 20
4
Wayne R Swanton
10 Mar 20
4
James DArecca
10 Mar 20
4
C. David Nicholson
4 Mar 20
4
Wayne R Swanton
4 Mar 20
4
James DArecca
4 Mar 20
4
William Meury
4 Mar 20
4
A Robert D Bailey
4 Mar 20
4
MATTHEW M WALSH
4 Mar 20
4
BRENT L SAUNDERS
4 Mar 20
5
CHRISTOPHER J COUGHLIN
13 Feb 20